



ELCC 2022 Industry Satellite Symposium

# INVITATION

## EVOLVING TREATMENT OPTIONS AND PRACTICES IN EGFR-MUTANT NSCLC

**Thursday**  
**31 March 2022**  
**Symposium**  
**13:30–15:00 CEST**  
Channel: Forum Hall

### STEERING COMMITTEE

**Antonio Passaro, Italy**  
**Enriqueta Felip, Spain**

### FACULTY

**Natasha Leighl, Canada**  
**Tony Mok, Hong Kong**  
**Benjamin Besse, France**  
**Anna Minchom, UK**

This exciting session will be streamed from the Forum Hall channel in the virtual Congress Centre. You will have the opportunity to submit your questions to the faculty for discussion during our live Q&A session.

### LEARNING OBJECTIVES

After attending this symposium, participants should be able to:

- Reflect on developments in the management of EGFR+ NSCLC, including treatment-resistant disease
- Evaluate the use of new and emerging therapeutic options for EGFR exon 20 insertion mutations in clinical practice

### AGENDA

- Welcome and introductions
- Unmet needs in the management of EGFR+ NSCLC
- Advances in the treatment of patients with EGFR exon20ins+ NSCLC
- Live Q&A and closing remarks



This invitation is for healthcare professionals only  
With the support of Janssen Pharmaceutical  
Companies of Johnson & Johnson in EMEA  
Janssen Pharmaceutica NV, Turnhoutseweg 30,  
B-2340 Beerse, Belgium  
Date of preparation: March 2022 EM-86642



PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Copyright © 2022 Janssen Pharmaceutica NV